Kalbe Farma Aims For Sales Growing 15 Percent In 2023

Rupiah (Photo: Doc. Antara)

JAKARTA - PT Kalbe Farma Tbk (KLBF) and its business entities are targeting net sales to grow by around 13 to 15 percent year on year (yoy) by 2023.

"The company targets net sales growth in 2023 to be around 13 to 15 percent, with a projected net profit growth per share of around 13 to 15 percent," said Kalbe Farma's Chief Financial Officer, Bernadus Karmin Winata quoting Antara, Wednesday, April 12.

The company maintains a capital expenditure (capex) of IDR 1.0 trillion in 2023, which will be used to expand production and distribution capacity.

In addition, the company maintains the dividend distribution ratio at 45 to 55 percent in 2023.

The company in the health sector recorded net sales reaching IDR 28.93 trillion in 2022, or an increase of 10.2 percent yoy compared to 2021.

With the increase in sales, the company recorded a net profit of IDR 3.38 trillion in 2022, or an increase of 6.2 percent from the previous IDR 3.18 trillion in 2021.

"The company always pays attention to the importance of managing supply chains, managing rising raw material costs with price increases policies, managing product portfolios, and maintaining operational cost efficiency," said Bernadus.

In terms of growth and contribution per division, in 2022, net sales of the health product division increased 14.6 percent yoy to IDR 4.15 trillion, with a contribution of 14.4 percent to the company's total net sales in 2022.

Then, net sales of distribution and logistics divisions increased 10.8 percent yoy to Rp 10.80 trillion, from the previous Rp 9.75 trillion in 2021, and contributed 37.3 percent to the company's total net sales.

Then, the nutrition division's net sales were recorded at IDR 7.83 trillion in 2022, or grew 9.3 percent yoy, and contributed 27.1 percent of the company's total net sales in 2022.

Meanwhile, net sales of the prescription drug division increased 7.5 percent to Rp6.14 trillion from the previous Rp5.71 trillion in 2021, and contributed 21.3 percent of the company's total net sales.

Kalbe Farma recorded an increase in operating profit of 5.2 percent yoy to IDR 4.23 trillion in 2022, with a ratio of operating profit to sales of 14.6 percent.

It was recorded that profit before income tax in 2022 amounted to IDR 4.45 trillion or grew 7.6 percent with a profit margin before income tax reaching 15.4 percent, and profit per share reached IDR 72.71 in 2022, or an increase of 7.1 percent yoy compared to IDR 67.92 in 2021.